Insmed Discontinues Brensocatib Development for Hidradenitis Suppurativa After Phase 2b Trial Fails to Meet Endpoints
核心洞察
Insmed's Phase 2b CEDAR study of brensocatib in moderate to severe hidradenitis suppurativa (搜索) failed to meet primary and secondary efficacy endpoints at both 10 mg and 40 mg doses.
The study showed paradoxical results with placebo achieving 57.1% reduction in abscess and inflammatory nodule count compared to 45.5% and 40.3% for the 10 mg and 40 mg brensocatib arms, respectively.
Despite the efficacy failure, brensocatib demonstrated good safety with no new safety signals identified, leading Insmed to discontinue the entire HS development program.
Insmed Incorporated announced that its Phase 2b CEDAR study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa (搜索) (HS) failed to meet its primary and secondary efficacy endpoints, prompting the company to discontinue its entire HS development program for the investigational therapy.
The randomized, double-blind, placebo-controlled study enrolled 214 patients across 72 sites globally, with participants receiving either brensocatib 10 mg, brensocatib 40 mg, or placebo once daily for 16 weeks. The primary endpoint measured percent change from baseline in total abscess and inflammatory nodule (AN) count at Week 16.
Unexpected Efficacy Results
The study revealed counterintuitive results that highlighted the challenges of developing treatments for HS. At Week 16, participants in the brensocatib 10 mg arm experienced a 45.5% reduction from baseline in total abscess and inflammatory nodule count, while those receiving 40 mg showed a 40.3% reduction. However, the placebo group demonstrated a superior 57.1% reduction, indicating that neither dose of brensocatib provided therapeutic benefit over placebo.
"The CEDAR study was designed as a proof-of-concept study to determine whether brensocatib could provide benefit for patients with HS—a disease where the lack of established animal models makes clinical development particularly challenging," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "While we are disappointed in the results, we hope that insights gained from this study will contribute to the broader scientific understanding of HS."
Safety Profile Maintained
Despite the efficacy failure, brensocatib maintained its established safety profile throughout the study. No new safety signals were identified for either dose, including the 40 mg arm, which represents the highest dose Insmed has studied to date. The company reported that brensocatib was well tolerated during the 16-week placebo-controlled treatment period, though specific treatment-emergent adverse event percentages were referenced but not detailed in the announcement.
Development Program Termination
Following these results, Insmed has made the strategic decision to discontinue its entire development program of brensocatib in hidradenitis suppurativa (搜索). The company plans to present the complete study data at a future medical congress, potentially contributing to the broader scientific understanding of this challenging inflammatory condition.
The CEDAR study's design included a continuation phase where participants either maintained their randomized brensocatib dose or, if initially on placebo, were randomized to receive either 10 mg or 40 mg of brensocatib after the initial 16-week period.
Clinical Development Challenges
The failure of the CEDAR study underscores the inherent difficulties in developing treatments for hidradenitis suppurativa (搜索), a chronic inflammatory skin condition. As noted by Insmed's Chief Medical Officer, the lack of established animal models for HS makes clinical development particularly challenging, requiring proof-of-concept studies in human patients to determine therapeutic potential.
Insmed expressed gratitude to the patients and investigators who participated in the study, acknowledging their contribution to advancing scientific understanding of this complex condition despite the disappointing efficacy outcomes.